Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: evidence from a nationwide nested case-control study paralleled with matched experimental models.

European heart journal open Pub Date : 2025-03-15 eCollection Date: 2025-05-01 DOI:10.1093/ehjopen/oeaf021

Callan D Wesley, Jarl Emanuel Strange, Anders Holt, Gunnar H Gislason, Cédric H G Neutel, Dustin N Krüger, Celine Civati, Mart Theunis, Tania Naessens, Lynn Roth, Guido R Y De Meyer, Wim Martinet, Peter Vibe Rasmussen, Pieter-Jan Guns

{"title":"Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: evidence from a nationwide nested case-control study paralleled with matched experimental models.","authors":"Callan D Wesley, Jarl Emanuel Strange, Anders Holt, Gunnar H Gislason, Cédric H G Neutel, Dustin N Krüger, Celine Civati, Mart Theunis, Tania Naessens, Lynn Roth, Guido R Y De Meyer, Wim Martinet, Peter Vibe Rasmussen, Pieter-Jan Guns","doi":"10.1093/ehjopen/oeaf021","DOIUrl":null,"url":null,"abstract":"Aims: Fluoroquinolones (FQ) have been associated with aortic aneurysm and aortic dissection (AA/AD) resulting in an official warning. Recently, large-scale epidemiological studies failed to confirm this.Methods and results: The current study aimed to scrutinize the FQ-AA/AD association through a retrospective nested case-cohort analysis supplemented with animal experimentation. FQ exposure was not associated with increased AA/AD hazard ratios in main and high-risk (elderly ≥65 years, hypertensive, and prevalent aortic disease) populations. Additionally, FQ did not cause increased mortality or aortic interventions in aortic disease patients. In addition, in animal experimentation, ciprofloxacin did not enlarge aortic diameters nor increase arterial stiffness.Conclusion: Conventional use of FQ should not be avoided when clinically indicated.","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"5 3","pages":"oeaf021"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062879/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European heart journal open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjopen/oeaf021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Fluoroquinolones (FQ) have been associated with aortic aneurysm and aortic dissection (AA/AD) resulting in an official warning. Recently, large-scale epidemiological studies failed to confirm this.

Methods and results: The current study aimed to scrutinize the FQ-AA/AD association through a retrospective nested case-cohort analysis supplemented with animal experimentation. FQ exposure was not associated with increased AA/AD hazard ratios in main and high-risk (elderly ≥65 years, hypertensive, and prevalent aortic disease) populations. Additionally, FQ did not cause increased mortality or aortic interventions in aortic disease patients. In addition, in animal experimentation, ciprofloxacin did not enlarge aortic diameters nor increase arterial stiffness.

Conclusion: Conventional use of FQ should not be avoided when clinically indicated.

查看原文本刊更多论文

氟喹诺酮类药物与主动脉瘤或主动脉夹层的风险：来自全国巢式病例对照研究的证据，与匹配的实验模型平行。

目的：氟喹诺酮类药物（FQ）与主动脉瘤和主动脉夹层（AA/AD）有关，导致官方警告。最近，大规模流行病学研究未能证实这一点。方法和结果：本研究旨在通过回顾性巢式病例队列分析和动物实验相结合，仔细研究FQ-AA/AD的关联。在主要人群和高危人群（≥65岁的老年人、高血压患者和主动脉疾病患者）中，FQ暴露与AA/AD风险比增加无关。此外，FQ不会导致主动脉疾病患者死亡率增加或主动脉干预。此外，在动物实验中，环丙沙星不会增大主动脉直径，也不会增加动脉硬度。结论：临床指征时不应避免常规使用FQ。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European heart journal open

CiteScore

2.80

自引率

0.00%

发文量